NXTC Q3 2020 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$17M

Net Income

-$16M

EPS (Diluted)

$-7.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$316M

Total Liabilities

$9M

Stockholders' Equity

$307M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	$0	-$7M	+100.0%
Operating Income	-$17M	-$10M	-79.3%
Net Income	-$16M	-$8M	-94.1%